Goodwin Procter advised the initial purchasers on the deal.Sarepta Therapeutics, Inc. announced its Rule 144A offering of 1.25% Convertible Senior Notes due 2027. The $1.15 billion offering…
Sarepta Therapeutics’ $1.15 Billion Notes Offering
Goodwin Procter advised the initial purchasers on the deal.Sarepta Therapeutics, Inc. announced its Rule 144A offering of 1.25% Convertible Senior Notes due 2027. The $1.15 billion offering…